Europe Dry Eye Syndrome Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Dry Eye Syndrome Market Size

• The Europe Dry Eye Syndrome Market size was valued at USD 1.92 Billion in 2024 and is expected to reach USD 3.18 Billion by 2032, at a CAGR of 6.50% during the forecast period
• This growth is driven by factors such as the Increasing prevalence of dry eyes among people, Increasing screen time

Dry Eye Syndrome Market Analysis

• Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a condition in which the surface of the affected person's eyes lacks lubrication or moisture. It's a common ailment that can strike anyone at any time.
• The demand for microscopes in the Europe Dry Eye Syndrome Market is significantly driven by the increasing prevalence of age-related eye conditions and advancements in surgical techniques

Report Scope and Dry Eye Syndrome Market Segmentation

Dry Eye Syndrome Market Trends

“Advancements in Operating Microscopes & 3D Visualization for Intraocular Surgery”

• One prominent trend in the evolution of operating microscopes and 3D visualization systems for intraocular surgery is the increasing integration of advanced optics and digital enhancements
• These innovations enhance surgical precision by offering high-definition, real-time visualization of intraocular structures, improving accuracy in delicate procedures
  • For instance, modern 3D visualization systems provide superior depth perception, enabling surgeons to navigate complex intraocular anatomy with greater clarity, which is particularly beneficial for vitreoretinal surgeries and minimally invasive glaucoma procedures.
• These advancements are transforming intraocular surgery, improving patient outcomes, and driving the demand for next-generation surgical microscopes with cutting-edge visualization capabilities

Dry Eye Syndrome Market Dynamics

Driver

“Increasing prevalence of dry eyes among people”

• The rising prevalence of dry eyes among people is a primary driver of the dry eye syndrome market's growth. Thyroid disorders, lupus, Sjogren’s syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people
• As the global population ages, the incidence of these conditions continues to grow, with older adults being more prone to various vision impairments that require surgical intervention
• As more individuals seek treatment for these conditions, the demand for operational microscopes rises, ensuring improved surgical outcomes and reducing the risks associated with eye surgeries
  • For instance, In December 2021, according to the article published by National Center for Biotechnology Information, the global population is aging rapidly, with Australia projected to have nearly 25% of its population aged 65 years and older by 2066. Older individuals experience significantly higher healthcare needs, including eye diseases
• As a result of the rising prevalence of eye diseases such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy, there is a significant increase in the demand for Dry Eye Syndromes

Opportunity

“Development of innovative treatments”

• There is an opportunity for pharmaceutical companies to invest in research and development of new and more effective treatments for dry eye syndrome. Novel medications and therapies can help address the unmet needs of patients with severe or chronic dry eye conditions.
• AI algorithms can analyze real-time images and provide instant feedback on surgical procedures, helping surgeons identify potential complications, such as retinal tears or detachment
• Additionally, AI-powered microscopes can also assist in image analysis, enabling surgeons to review and compare images, track patient progress, and make more accurate diagnoses
  • For instance, In January 2025, according to an article published in the JMA Journal, AI algorithms, particularly those based on deep learning, can analyze retinal images with high accuracy, identifying and grading the severity of DR. These systems can quickly and efficiently process large volumes of images, reducing the burden on ophthalmologists and improving screening coverage. The ability of AI to detect early-stage DR and predict disease progression is crucial for timely intervention, which can significantly delay or even reverse the progression of the disease
• The integration of AI in ophthalmic microscopes can also lead to improved patient outcomes, reduced recovery times, and enhanced quality of life. By leveraging AI-powered image analysis, surgeons can identify patients at risk for complications and take proactive measures to prevent them.

Restraint/Challenge

“High treatment costs”

• The high cost of Dry Eye Syndromes poses a significant challenge for the market, particularly affecting the purchasing decisions of healthcare facilities, especially in developing regions
• These microscopes, which are essential for performing intricate eye surgeries, can often range from tens of thousands to several hundred thousand dollars
• This substantial financial barrier can deter smaller clinics and hospitals with limited budgets from upgrading their equipment or investing in new technologies, leading to a reliance on outdated tools
  • For instance, In November 2024, according to an article published by the Ningbo Haishu HONYU Opto-Electro Co., Ltd, one of the main concerns surrounding the high cost of ophthalmic surgical microscopes is its potential impact on healthcare affordability and accessibility. The high cost of ophthalmic surgical microscopes adds to this burden, as it limits the ability of healthcare facilities to invest in the latest technology and equipment, thereby affecting the quality of care provided to patients
• Consequently, such limitations can result in disparities in the quality of care and access to advanced surgical procedures, ultimately hindering the overall growth of the market

Dry Eye Syndrome Market Scope

The market is segmented on the basis product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel.

In 2025, the Tear stimulators is projected to dominate the market with a largest share in application segment

The Tear Stimulators segment is anticipated to lead the Europe Dry Eye Syndrome Market, capturing a significant share of 56.22% by 2025, driven by its widespread prevalence and the demand for precision treatments. As a primary method for vision restoration, advancements in surgical techniques and microscope technologies will improve outcomes, fueling market expansion. Additionally, the growing aging population and increasing rates of cataracts are expected to further solidify its dominance in the market.

The Lubricating Agent is expected to account for the largest share during the forecast period in technology market

In 2025, the Lubricating Agent segment is projected to dominate the Europe Dry Eye Syndrome Market, securing the largest share at 51.31% due to its high prevalence and demand for precision care. As a primary therapeutic option for alleviating symptoms, improvements in formulation and delivery methods will enhance treatment outcomes, driving market growth. Additionally, the aging population and an increase in cataract cases will further support the segment's market leadership.

Dry Eye Syndrome Market Regional Analysis

“Germany Holds the Largest Share in the Dry Eye Syndrome Market”

• Germany dominates the Dry Eye Syndrome market, driven by advanced healthcare infrastructure, high adoption of cutting-edge medical technologies, and strong presence of key market players

• The Germany holds a significant share in the Europe Dry Eye Syndrome Market due to increased demand for high-precision ophthalmic procedures, a rising prevalence of eye disorders such as cataracts and glaucoma, and continuous advancements in surgical techniques
• The availability of well-established reimbursement policies and growing investments in research & development by leading medical device companies further strengthen the market.
• In addition, the increasing number of ophthalmic surgeries, including cataract and refractive procedures, along with a high rate of adoption of minimally invasive techniques, is fueling market expansion across the region

“U.K. is Projected to Register the Highest CAGR in the Dry Eye Syndrome Market”

• U.K. is expected to witness the highest growth rate in the Dry Eye Syndrome market, driven by rapid expansion in healthcare infrastructure, increasing awareness about eye health, and rising surgical volumes
• Countries such as U.K. and Germany are emerging as key markets due to the growing aging population, which is more susceptible to conditions such as cataracts, diabetic retinopathy, and macular degeneration
• U.K., with its advanced medical technology and increasing number of ophthalmic surgeons, remains a crucial market for ophthalmic microscopes. The country continues to lead in the adoption of premium surgical equipment to enhance precision and efficiency in eye surgeries
• U.K. with their large populations and rising cases of vision-related disorders, are witnessing increased government and private sector investments in modern ophthalmic surgical setups. The expanding presence of global medical device manufacturers and improving accessibility to advanced ophthalmic care further contribute to market growth

Dry Eye Syndrome Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Allergan (Ireland),
• Bausch & Lomb Incorporated (U.S.),
• Novartis Ag (Switzerland),
• Johnson & Johnson Private Limited (India),
• Prestige Consumer Healthcare (U.S.),
• Akorn Operating Company LLC (U.S.),
• Sun Pharmaceutical Industries Ltd. (India),
• Teva Pharmaceutical Industries Ltd. (Israel),
• Novaliq Gmbh (Germany),
• Santen Pharmaceutical Co., Ltd. (Japan),
• Cardinal Health (U.S.),
• Alembic Pharmaceuticals Limited (India),
• Cipla Inc. (India),
• Perrigo Company Plc (Ireland),
• Senju Pharmaceutical Co. Ltd. (Japan),
• Horus Pharma (France),
• Rohto Pharmaceutical Co., Ltd. (Japan),
• Visufarma (Italy),
• Hubrx Ltd (UK)

Latest Developments in Europe Dry Eye Syndrome Market

• In October 2024, Novaliq and Laboratoires Théa announced that, Vevizye received approval from Europen commission to market the product for treating dry eye disease in adults. It is the first and only water-free ciclosporin 0.1% eye drop solution to receive approval in Europe.
• In June 2024, Oculis reported Phase 2b positive results for licaminlimab, anti-TNFα eye drop, shows significant improvement in multiple DED signs. The drug, effective in patients with a specific TNFR1 genetic biomarker, demonstrated rapid and notable reduction in corneal inflammation. Licaminlimab was well tolerated with similar side effects to a vehicle.
• In May 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel, a novel dry eye treatment cleared by the FDA. This cross-linked hyaluronic acid gel temporarily blocks tear drainage by occluding the canalicular system, allowing natural tears to bathe the eyes. Administered via a simple in-office procedure, it lasts for six months and is reimbursed under CPT code 68761. Nordic Pharma is showcasing LACRIFILL at Kiawah Eye 2024, highlighting its potential to enhance ophthalmic practices. Nordic Pharma, part of SEVER Life Sciences, focuses on specialty pharmaceuticals and has a global presence.

SKU-44907